Summary
Karim Ghoufiri
Business Developer
TECHNOLOGY
- A method for assessing the risk of developing atrial cardiomyopathy in diabetic patients using magnetic resonance imaging, taking into account two parameters: (i) assessment of epicardial adipose tissue around the Groove sulcus and (ii) analysis of atrial deformation.
MARKET
- Currently, no biomarker on the market has the ability to provide subclinical disease detection and predictive information.
- Early identification, through subclinical predictive factors, would enable early management of atrial cardiomyopathy.
- Preferred applications: patients with diabetes and hypertension.
DEVELOPMENT STATUS
- PoC was performed both in silico and in vivo on the Metacardis cohort comprising 100 patients, demonstrating an AUC of 0.95.
- However, confirmation of these results is required across other larger cohorts.
IP
- PCT patent application filed on 2023/10/13 and published under No. WO/2025/078852.
VALORISATION STRATEGY
- Licensing